Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics.

At day 1, all bivalent antibodies were present in serum at similar concentrations (1000–3000 nM), comparable to a non-targeted control IgG (~2500 nM), with only a slight trend toward higher levels for weaker binding antibodies ( Figure 3A ).

also in 3,004 other papers